Trofosfamide in non-Hodgkin's lymphoma. A phase II study

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Malignant non-Hodgkin's lymphoma is a significant hematologic malignancy.
• Effective and tolerable treatment options are crucial for elderly patients.
• Trofosfamide is an alkylating agent with potential in lymphoma treatment.

Purpose of the Study:

• To evaluate the efficacy and safety of oral trofosfamide in patients with malignant non-Hodgkin's lymphoma.
• To determine the overall response rate and duration of response.
• To assess the toxicity profile of trofosfamide in this patient population.

Main Methods:

• A cohort of 23 patients with malignant non-Hodgkin's lymphoma received oral trofosfamide 50 mg three times daily.
• Patients were assessed for response, including complete response (CR) and partial response (PR).
• Adverse events, particularly hematological toxicity, were closely monitored.

Main Results:

• An overall response rate of 61% was observed (22% CR, 39% PR).
• The median duration of response was 4 months.
• The primary toxicity was bone marrow depression, with 7 patients experiencing grade II or III hematological toxicity; however, gastrointestinal, renal, and neurotoxicity were absent, and hair loss was not reported.

Conclusions:

• Oral trofosfamide demonstrates significant efficacy in treating malignant non-Hodgkin's lymphoma.
• The drug is generally well-tolerated, with a favorable side-effect profile, notably lacking gastrointestinal, renal, and neurotoxicity.
• Trofosfamide represents a viable treatment option, especially for elderly patients with lymphoma, due to its good subjective tolerance and manageable toxicity.